NCT03367273

Brief Summary

study \& verify the hypothesis of the involvement of TSLP in the pathogenesis of vitiligo in comparison to their levels in the healthy control persons.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2017

Shorter than P25 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2017

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2017

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

December 5, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 8, 2017

Completed
Last Updated

December 20, 2017

Status Verified

December 1, 2017

Enrollment Period

6 months

First QC Date

December 5, 2017

Last Update Submit

December 18, 2017

Conditions

Vitiligo

Outcome Measures

Primary Outcomes (1)

  • Expression levels of TSLP in patients of Vitiligo.

    7 months

Study Arms (2)

vitiligo patients

EXPERIMENTAL
Other: skin biopsy

controls

EXPERIMENTAL
Other: skin biopsy

Interventions

skin biopsyOTHER

Lesional skin biopsy was taken from every patient. Also a skin biopsy was taken from every control subject

controlsvitiligo patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with generalized non-segmental vitiligo.
  • Both sexes.
  • Age \< 18 years old age.
  • New cases or cases not receiving any medication for at least 3 months ago.

You may not qualify if:

  • Age: Patients \< 18 years.
  • Segmental or universal vitiligo.
  • Pregnant and lactating females. Autoimmune diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Vitiligo

Condition Hierarchy (Ancestors)

HypopigmentationPigmentation DisordersSkin DiseasesSkin and Connective Tissue Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

December 5, 2017

First Posted

December 8, 2017

Study Start

January 1, 2017

Primary Completion

July 1, 2017

Study Completion

July 1, 2017

Last Updated

December 20, 2017

Record last verified: 2017-12